References
1. Ronco P, Beck L, Debiec H, Fervenza FC, Hou FF, Jha V et al: Membranous nephropathy. Nature reviews Disease primers 2021, 7(1):69. 2. Adak A, Khan MR: An insight into gut microbiota and its functionalities. Cell Mol Life Sci 2019, 76(3):473-493. 3. Liu X, Chen Y, Zhang S, Dong L: Gut microbiota-mediated immunomodulation in tumor. Journal of experimental & clinical cancer research : CR 2021, 40(1):221. 4. Ling Z, Liu X, Cheng Y, Yan X, Wu S: Gut microbiota and aging.Critical reviews in food science and nutrition 2022, 62(13):3509-3534. 5. Patterson E, Ryan PM, Cryan JF, Dinan TG, Ross RP, Fitzgerald GF et al: Gut microbiota, obesity and diabetes. Postgraduate medical journal 2016, 92(1087):286-300. 6. Wang F, Li N, Ni S, Min Y, Wei K, Sun H et al: The Effects of Specific Gut Microbiota and Metabolites on IgA Nephropathy-Based on Mendelian Randomization and Clinical Validation. Nutrients 2023, 15(10). 7. Zhang B, Wan Y, Zhou X, Zhang H, Zhao H, Ma L et al: Characteristics of Serum Metabolites and Gut Microbiota in Diabetic Kidney Disease.Frontiers in pharmacology 2022, 13:872988. 8. Huang Y, Xin W, Xiong J, Yao M, Zhang B, Zhao J: The Intestinal Microbiota and Metabolites in the Gut-Kidney-Heart Axis of Chronic Kidney Disease. Frontiers in pharmacology 2022, 13:837500. 9. Zhou G, Zeng J, Peng L, Wang L, Zheng W, Di W et al: Fecal microbiota transplantation for membranous nephropathy. CEN case reports2021, 10(2):261-264. 10. Lawlor DA, Harbord RM, Sterne JA, Timpson N, Davey Smith G: Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. Statistics in medicine 2008, 27(8):1133-1163. 11. Boef AG, Dekkers OM, le Cessie S: Mendelian randomization studies: a review of the approaches used and the quality of reporting.International journal of epidemiology 2015, 44(2):496-511. 12. Kurilshikov A, Medina-Gomez C, Bacigalupe R, Radjabzadeh D, Wang J, Demirkan A et al: Large-scale association analyses identify host factors influencing human gut microbiome composition. Nature genetics2021, 53(2):156-165. 13. Mendoza-León MJ, Mangalam AK, Regaldiz A, González-Madrid E, Rangel-Ramírez MA, Álvarez-Mardonez O et al: Gut microbiota short-chain fatty acids and their impact on the host thyroid function and diseases.Frontiers in endocrinology 2023, 14:1192216. 14. Ni JJ, Xu Q, Yan SS, Han BX, Zhang H, Wei XT et al: Gut Microbiota and Psychiatric Disorders: A Two-Sample Mendelian Randomization Study.Frontiers in microbiology 2021, 12:737197. 15. Burgess S, Thompson SG: Use of allele scores as instrumental variables for Mendelian randomization. International journal of epidemiology 2013, 42(4):1134-1144. 16. Ren F, Jin Q, Liu T, Ren X, Zhan Y: Causal effects between gut microbiota and IgA nephropathy: a bidirectional Mendelian randomization study. Front Cell Infect Microbiol 2023, 13:1171517. 17. Bowden J, Davey Smith G, Burgess S: Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. International journal of epidemiology 2015, 44(2):512-525. 18. Burgess S: Sample size and power calculations in Mendelian randomization with a single instrumental variable and a binary outcome.International journal of epidemiology 2014, 43(3):922-929. 19. Zhou S, Zhang Q, Gao Y, Liu F, Cao W, Li Z et al: Sargassum fusiforme together with turmeric extract and pomegranate peel extract alleviates obesity in high fat-fed C57BL/6J mice. Food & function 2021, 12(10):4654-4669. 20. Hu C, Rzymski P: Non-Photosynthetic Melainabacteria (Cyanobacteria) in Human Gut: Characteristics and Association with Health. Life (Basel, Switzerland) 2022, 12(4). 21. Huang B, Chau SWH, Liu Y, Chan JWY, Wang J, Ma SL et al: Gut microbiome dysbiosis across early Parkinson’s disease, REM sleep behavior disorder and their first-degree relatives. Nature communications 2023, 14(1):2501. 22. Vaziri ND, Wong J, Pahl M, Piceno YM, Yuan J, DeSantis TZ et al: Chronic kidney disease alters intestinal microbial flora. Kidney international 2013, 83(2):308-315. 23. Jiang Z, Zhuo LB, He Y, Fu Y, Shen L, Xu F et al: The gut microbiota-bile acid axis links the positive association between chronic insomnia and cardiometabolic diseases. Nature communications2022, 13(1):3002. 24. Azzouz D, Omarbekova A, Heguy A, Schwudke D, Gisch N, Rovin BH et al: Lupus nephritis is linked to disease-activity associated expansions and immunity to a gut commensal. Ann Rheum Dis 2019, 78(7):947-956. 25. He H, Lin M, You L, Chen T, Liang Z, Li D et al: Gut Microbiota Profile in Adult Patients with Idiopathic Nephrotic Syndrome.Biomed Res Int 2021, 2021:8854969. 26. Iino T, Mori K, Tanaka K, Suzuki KI, Harayama S: Oscillibacter valericigenes gen. nov., sp. nov., a valerate-producing anaerobic bacterium isolated from the alimentary canal of a Japanese corbicula clam. Int J Syst Evol Microbiol 2007, 57(Pt 8):1840-1845. 27. Lee GH, Kumar S, Lee JH, Chang DH, Kim DS, Choi SH et al: Genome sequence of Oscillibacter ruminantium strain GH1, isolated from rumen of Korean native cattle. J Bacteriol 2012, 194(22):6362. 28. Zhai Q, Qu D, Feng S, Yu Y, Yu L, Tian F et al: Oral Supplementation of Lead-Intolerant Intestinal Microbes Protects Against Lead (Pb) Toxicity in Mice. Front Microbiol 2019, 10:3161. 29. Stanford J, Charlton K, Stefoska-Needham A, Ibrahim R, Lambert K: The gut microbiota profile of adults with kidney disease and kidney stones: a systematic review of the literature. BMC Nephrol 2020, 21(1):215. 30. Moroishi Y, Gui J, Nadeau KC, Morrison HG, Madan J, Karagas MR: A prospective study of the infant gut microbiome in relation to vaccine response. Pediatr Res 2023, 93(3):725-731. 31. Round JL, Mazmanian SK: Inducible Foxp3+ regulatory T-cell development by a commensal bacterium of the intestinal microbiota.Proc Natl Acad Sci U S A 2010, 107(27):12204-12209. 32. Atarashi K, Tanoue T, Oshima K, Suda W, Nagano Y, Nishikawa H et al: Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota. Nature 2013, 500(7461):232-236. 33. Arpaia N, Campbell C, Fan X, Dikiy S, van der Veeken J, deRoos P et al: Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature 2013, 504(7480):451-455. 34. Elce A, Amato F, Zarrilli F, Calignano A, Troncone R, Castaldo G et al: Butyrate modulating effects on pro-inflammatory pathways in human intestinal epithelial cells. Benef Microbes 2017, 8(5):841-847. 35. Cao RR, He P, Lei SF: Novel microbiota-related gene set enrichment analysis identified osteoporosis associated gut microbiota from autoimmune diseases. J Bone Miner Metab 2021, 39(6):984-996. 36. Chen L, Wang D, Garmaeva S, Kurilshikov A, Vich Vila A, Gacesa R et al: The long-term genetic stability and individual specificity of the human gut microbiome. Cell 2021, 184(9):2302-2315.e2312. 37. David LA, Maurice CF, Carmody RN, Gootenberg DB, Button JE, Wolfe BE et al: Diet rapidly and reproducibly alters the human gut microbiome.Nature 2014, 505(7484):559-563. 38. Zhang J, Luo D, Lin Z, Zhou W, Rao J, Li Y et al: Dysbiosis of gut microbiota in adult idiopathic membranous nephropathy with nephrotic syndrome. Microbial pathogenesis 2020, 147:104359. 39. Zhao J, Bai M, Ning X, Qin Y, Wang Y, Yu Z et al: Expansion of Escherichia-Shigella in Gut Is Associated with the Onset and Response to Immunosuppressive Therapy of IgA Nephropathy. J Am Soc Nephrol2022, 33(12):2276-2292. 40. Chávez-Iñiguez JS, Villegas-Gutiérrez LY, Gallardo-González AM: Acute Kidney Injury and Intestinal Dysbiosis. Front Nephrol 2022, 2:916151. 41. Nallu A, Sharma S, Ramezani A, Muralidharan J, Raj D: Gut microbiome in chronic kidney disease: challenges and opportunities. Transl Res 2017, 179:24-37. 42. Lee YK, Mazmanian SK: Has the microbiota played a critical role in the evolution of the adaptive immune system? Science 2010, 330(6012):1768-1773. 43. Ivanov, II, Frutos Rde L, Manel N, Yoshinaga K, Rifkin DB, Sartor RB et al: Specific microbiota direct the differentiation of IL-17-producing T-helper cells in the mucosa of the small intestine. Cell Host Microbe 2008, 4(4):337-349. 44. Li H, Boulougoura A, Endo Y, Tsokos GC: Abnormalities of T cells in systemic lupus erythematosus: new insights in pathogenesis and therapeutic strategies. J Autoimmun 2022, 132:102870. 45. Chi M, Ma K, Wang J, Ding Z, Li Y, Zhu S et al: The Immunomodulatory Effect of the Gut Microbiota in Kidney Disease. J Immunol Res2021, 2021:5516035. 46. Neavin DR, Liu D, Ray B, Weinshilboum RM: The Role of the Aryl Hydrocarbon Receptor (AHR) in Immune and Inflammatory Diseases.Int J Mol Sci 2018, 19(12). 47. Miao H, Wang YN, Yu XY, Zou L, Guo Y, Su W et al: Lactobacillus species ameliorate membranous nephropathy through inhibiting the aryl hydrocarbon receptor pathway via tryptophan-produced indole metabolites.Br J Pharmacol 2023. 48. Zhang Y, Zhao J, Qin Y, Wang Y, Yu Z, Ning X et al: Specific alterations of gut microbiota in patients with membranous nephropathy: A systematic review and meta-analysis. Frontiers in physiology2022, 13:909491.